肝细胞癌(HCC)占原发性肝癌80％以上,由于诊断不及时、化疗失败和复发频繁等因素,患者预后很差.MicroRNA(miRNA)是一类内源性非编码RNA,其在肝恶性肿瘤中靶向抑制mRNA的翻译,可以调节肝癌细胞的增殖、凋亡、迁移和侵袭,同时在诊断标志物和基因靶向治疗中展示出了巨大潜力.本文旨在探讨HCC发展过程中miRNA的作用机制及其诊断和治疗HCC的研究进展.
Hepatocellular carcinoma(HCC)accounts for more than 80％of primary liver cancer,and the prognosis of patients is very poor due to factors such as untimely diagnosis,failure of chemotherapy and frequent recurrence.MicroRNA is a kind of endogenous noncoding RNA,which can inhibit the translation of messenger RNA in liver malignant tumors,regulate the proliferation,apoptosis,migration and invasion of HCC cells,and play an important role in the development of HCC.Therefore,the mechanism of miRNAs in the development of HCC and its research progress in diagnosis and treatment are deeply discussed.
陈大维;王智馨;李衡;李三强
河南科技大学基础医学与法医学院肝脏损伤与修复分子医学重点实验室,河南洛阳 471003河南科技大学基础医学与法医学院肝脏损伤与修复分子医学重点实验室,河南洛阳 471003||河南省肝病防治工程技术研究中心,河南洛阳 471003
药学
microRNA;肝细胞癌;肿瘤调节;生物标志物;治疗靶点
microRNA;hepatocellular carcinoma;tumor regulation;biomarker;therapeutic target
《中国临床药理学杂志》 2024 (008)
1231-1235 / 5
河南省高等学校重点科研项目计划基础研究专项基金资助项目(23ZX006)
10.13699/j.cnki.1001-6821.2024.08.030
评论